Results 161 to 170 of about 19,206,393 (242)

Two-Stage Double-Arm Trial Optimal Design of Restricted Mean Survival Time With Sculpted Critical Region. [PDF]

Stat Med
He J, Lin R, Chen Y, Lam KF.
europepmc   +1 more source

Are restricted mean survival time methods especially useful for noninferiority trials? [PDF]

Clin Trials, 2021
Freidlin B, Hu C, Korn EL.
europepmc   +1 more source

Understanding and Mitigating the Risk of Accelerated Biological Aging in Survivors of Cancer: A Scoping Review

Aging and Cancer, EarlyView.
Cancer treatment is associated with measurable acceleration of biological aging across epigenetic, telomere, senescence, and immune biomarkers. However, biomarker validation and interventional strategies remain limited, especially in hematologic malignancies, underscoring the need for standardized multi‐omic aging assessments and adequately powered ...
Moataz Ellithi, Emily Herdman, Danielle Westmark, Vijaya R. Bhatt   +3 more
wiley   +1 more source

Beyond the Hazard Ratio: Rethinking Survival Reporting in Cardio-Oncology With Restricted Mean Survival Time. [PDF]

JACC CardioOncol
Maselli-Schoueri JH, Saibil SD, Gabriel da Silva Negrini V, Neto AS, Butler M.   +4 more
europepmc   +1 more source

Regression modeling of restricted mean survival time for left-truncated right-censored data. [PDF]

Stat Med, 2022
Rong R, Ning J, Zhu H.
europepmc   +1 more source

Risk of Non‐Arteritic Anterior Ischemic Optic Neuropathy in Idiopathic Intracranial Hypertension Patients Treated with GLP‐1 Receptor Agonists

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Introduction Glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs) have demonstrated significant weight‐reducing effects and may offer benefits in idiopathic intracranial hypertension (IIH); however, recent concerns about the risk of non‐arteritic anterior ischemic optic neuropathy (NAION) have emerged.
Faisal A. Al‐Harbi, Mohanad A. Alkuwaiti, Yazeed B. Alaql, Ahmed K. Alsaif, Ahmed A. Alessa, Meshari Ayed Alharbi, Mohammed Alfalah, Saud A. Alnaaim, Sajjad M. AlHaddad, Ahmed Y. Azzam   +9 more
wiley   +1 more source

Comparative Effectiveness of Oral Fluoropyrimidines Versus FOLFOX as Adjuvant Therapy for Stage III Colon Cancer: A Retrospective Cohort Study Using Overlap-Weighted Restricted Mean Survival Time Analysis. [PDF]

Pharmacoepidemiol Drug Saf
Huang SF, Hsu CW, Wu CC, Chen YH.
europepmc   +1 more source

Restricted mean survival time versus conventional measures for treatment decision-making. [PDF]

J Am Geriatr Soc, 2021
Kim DH, Shi SM, Carroll D, Najafzadeh M, Wei LJ.   +4 more
europepmc   +1 more source

Comparative Effectiveness and Safety of Inebilizumab Versus Rituximab in AQP4‐IgG‐Positive NMOSD

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective Rituximab (anti‐CD20, RTX) and inebilizumab (anti‐CD19, INE) represent B‐cell‐depleting therapies used for aquaporin‐4 antibody‐positive (AQP4‐IgG+) neuromyelitis optica spectrum disorder (NMOSD); however, direct comparative evidence remains limited.
Jie Lin, Binbin Xue, Dewei Xie, Jia Li, Juyuan Pan, Lanbing Zhu, Qiaowen Tong, Jing Lin, Ruofan Zhu, Xu Zhang, Junhui Xia, Xiang Li   +11 more
wiley   +1 more source

Why restricted mean survival time methods are especially useful for non-inferiority trials. [PDF]

Clin Trials, 2021
Quartagno M, Morris TP, White IR.
europepmc   +1 more source